Top-Rated StocksTop-RatedNASDAQ:VTYX Ventyx Biosciences (VTYX) Stock Forecast, Price & News $35.47 +0.67 (+1.93%) (As of 06/7/2023 ET) Add Compare Share Share Today's Range$34.94▼$36.1950-Day Range$28.53▼$39.5552-Week Range$11.07▼$47.25Volume877,697 shsAverage Volume632,357 shsMarket Capitalization$1.91 billionP/E RatioN/ADividend YieldN/APrice Target$55.40 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ventyx Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside56.2% Upside$55.40 Price TargetShort InterestBearish19.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.43Based on 7 Articles This WeekInsider TradingSelling Shares$18.32 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.76) to ($3.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 starsMedical Sector597th out of 981 stocksPharmaceutical Preparations Industry278th out of 460 stocks 3.5 Analyst's Opinion Consensus RatingVentyx Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $55.40, Ventyx Biosciences has a forecasted upside of 56.2% from its current price of $35.47.Amount of Analyst CoverageVentyx Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.19% of the float of Ventyx Biosciences has been sold short.Short Interest Ratio / Days to CoverVentyx Biosciences has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Ventyx Biosciences has recently increased by 6.17%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldVentyx Biosciences does not currently pay a dividend.Dividend GrowthVentyx Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VTYX. Previous Next 0.9 News and Social Media Coverage News SentimentVentyx Biosciences has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.51 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ventyx Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 1 people have searched for VTYX on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ventyx Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $18,319,051.00 in company stock.Percentage Held by Insiders24.39% of the stock of Ventyx Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.57% of the stock of Ventyx Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Ventyx Biosciences are expected to decrease in the coming year, from ($2.76) to ($3.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ventyx Biosciences is -15.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ventyx Biosciences is -15.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVentyx Biosciences has a P/B Ratio of 5.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ventyx Biosciences (NASDAQ:VTYX) StockVentyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company is developing VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.Read More Receive VTYX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ventyx Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address VTYX Stock News HeadlinesJune 7, 2023 | finance.yahoo.comVentyx Biosciences Announces Completion of Enrollment of the Phase 2 Trial of VTX002 in Ulcerative Colitis and the Phase 2 Trial of VTX958 in Plaque PsoriasisJune 4, 2023 | americanbankingnews.comWilliam J. Sandborn Sells 10,629 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) StockJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 25, 2023 | americanbankingnews.comAnalysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Price Target at $55.40May 18, 2023 | americanbankingnews.comWilliam J. Sandborn Sells 3,487 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) StockMay 12, 2023 | markets.businessinsider.comVentyx Biosciences (VTYX) Gets a Buy from LifeSci CapitalMay 12, 2023 | markets.businessinsider.comThe Latest Analyst Ratings for Ventyx BiosciencesMay 12, 2023 | msn.comPreview: Ventyx Biosciences's EarningsJune 8, 2023 | Edge On The Street (Ad)Graphite Shortage Could Derail the $7 Trillion EV TransitionGraphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.May 12, 2023 | finance.yahoo.comQ1 2023 Ventyx Biosciences Inc Earnings CallMay 12, 2023 | finanznachrichten.deVentyx Biosciences, Inc.: Ventyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressMay 12, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Ventyx Biosciences (VTYX)May 12, 2023 | markets.businessinsider.comVentyx Biosciences (VTYX) Receives a Buy from Goldman SachsMay 11, 2023 | msn.comRecap: Ventyx Biosciences Q1 EarningsMay 11, 2023 | finance.yahoo.comVentyx Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressMay 9, 2023 | americanbankingnews.comVentyx Biosciences (VTYX) Scheduled to Post Quarterly Earnings on ThursdayMay 8, 2023 | americanbankingnews.comVentyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan Sells 30,000 SharesMay 4, 2023 | finance.yahoo.comVentyx Biosciences to Report First Quarter 2023 Financial Results on May 11, 2023May 4, 2023 | americanbankingnews.comInsider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Insider Sells 10,790 Shares of StockMay 2, 2023 | americanbankingnews.comAnalysts Set Ventyx Biosciences, Inc. (NASDAQ:VTYX) Target Price at $55.40May 2, 2023 | americanbankingnews.comFinancial Analysis: Ventyx Biosciences (VTYX) versus Its PeersApril 30, 2023 | americanbankingnews.comVentyx Biosciences, Inc. (NASDAQ:VTYX) Sees Significant Decline in Short InterestApril 28, 2023 | americanbankingnews.comInsider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Major Shareholder Sells 8,642 Shares of StockApril 28, 2023 | americanbankingnews.comVentyx Biosciences, Inc. (NASDAQ:VTYX) CFO Martin Auster Sells 28,000 SharesApril 28, 2023 | americanbankingnews.comInsider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) Major Shareholder Sells $3,499,431.60 in StockApril 27, 2023 | americanbankingnews.comSomu Subramaniam Sells 793 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) StockApril 22, 2023 | americanbankingnews.comInsider Selling: Ventyx Biosciences, Inc. (NASDAQ:VTYX) CFO Sells $231,000.00 in StockSee More Headlines VTYX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VTYX Company Calendar Last Earnings3/23/2023Today6/08/2023Next Earnings (Estimated)8/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VTYX CUSIPN/A CIK1851194 Webwww.ventyxbio.com Phone760-593-4832FaxN/AEmployees27Year FoundedN/APrice Target and Rating Average Stock Price Forecast$55.40 High Stock Price Forecast$77.00 Low Stock Price Forecast$35.00 Forecasted Upside/Downside+56.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($2.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-108,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-36.87% Return on Assets-34.54% Debt Debt-to-Equity RatioN/A Current Ratio23.44 Quick Ratio23.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.25 per share Price / Book5.68Miscellaneous Outstanding Shares58,350,000Free Float44,118,000Market Cap$2.07 billion OptionableNot Optionable Beta-0.36 Key ExecutivesDr. Sheila K. Gujrathi M.D. (Age 53)Exec. Chair Comp: $81.14kDr. Raju S. Mohan Ph.D. (Age 65)Founder, CEO & Director Comp: $783.73kDr. John M. Nuss Ph.D. (Age 64)Chief Scientific Officer Comp: $5.57MMr. Christopher W. Krueger J.D. (Age 55)MBA, Chief Bus. Officer Comp: $568.14kProf. William J. Sandborn M.D.Ph.D., Pres & Chief Medical OfficerDr. Martin Douglas Auster M.D. (Age 48)Chief Financial Officer More ExecutivesKey CompetitorsAbCellera BiologicsNASDAQ:ABCLSupernus PharmaceuticalsNASDAQ:SUPNHUTCHMEDNASDAQ:HCMHarmony BiosciencesNASDAQ:HRMYRocket PharmaceuticalsNASDAQ:RCKTView All CompetitorsInsiders & InstitutionsMartin AusterSold 28,000 sharesTotal: $969,920.00 ($34.64/share)Raju MohanSold 30,000 sharesTotal: $1.03 M ($34.36/share)Christopher W KruegerSold 15,000 sharesTotal: $515,400.00 ($34.36/share)William J SandbornSold 10,629 sharesTotal: $364,149.54 ($34.26/share)ProShare Advisors LLCSold 1,031 shares on 5/26/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions VTYX Stock - Frequently Asked Questions Should I buy or sell Ventyx Biosciences stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ventyx Biosciences in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VTYX shares. View VTYX analyst ratings or view top-rated stocks. What is Ventyx Biosciences' stock price forecast for 2023? 8 equities research analysts have issued 1 year price targets for Ventyx Biosciences' stock. Their VTYX share price forecasts range from $35.00 to $77.00. On average, they anticipate the company's share price to reach $55.40 in the next year. This suggests a possible upside of 56.2% from the stock's current price. View analysts price targets for VTYX or view top-rated stocks among Wall Street analysts. How have VTYX shares performed in 2023? Ventyx Biosciences' stock was trading at $32.79 on January 1st, 2023. Since then, VTYX shares have increased by 8.2% and is now trading at $35.47. View the best growth stocks for 2023 here. When is Ventyx Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023. View our VTYX earnings forecast. How were Ventyx Biosciences' earnings last quarter? Ventyx Biosciences, Inc. (NASDAQ:VTYX) issued its quarterly earnings results on Thursday, March, 23rd. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by $0.03. What ETFs hold Ventyx Biosciences' stock? ETFs with the largest weight of Ventyx Biosciences (NASDAQ:VTYX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Alger Mid Cap 40 ETF (FRTY), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC), First Trust Multi-Manager Small Cap Opportunities ETF (MMSC) and Nuveen Small Cap Select ETF (NSCS). When did Ventyx Biosciences IPO? (VTYX) raised $152 million in an initial public offering on Thursday, October 21st 2021. The company issued 9,472,656 shares at a price of $15.00-$17.00 per share. What is Ventyx Biosciences' stock symbol? Ventyx Biosciences trades on the NASDAQ under the ticker symbol "VTYX." Who are Ventyx Biosciences' major shareholders? Ventyx Biosciences' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (13.35%), Price T Rowe Associates Inc. MD (4.71%), BlackRock Inc. (3.60%), RTW Investments LP (2.44%), Wellington Management Group LLP (1.53%) and Pictet Asset Management SA (1.31%). Insiders that own company stock include Christopher W Krueger, Global Strategic Fund I Venbio, John Nuss, Martin Auster, Nsv Partners Iii Lp, Raju Mohan, Sheila Gujrathi, Somu Subramaniam, William J Sandborn and William Richard White. View institutional ownership trends. How do I buy shares of Ventyx Biosciences? Shares of VTYX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ventyx Biosciences' stock price today? One share of VTYX stock can currently be purchased for approximately $35.47. How much money does Ventyx Biosciences make? Ventyx Biosciences (NASDAQ:VTYX) has a market capitalization of $2.07 billion. The company earns $-108,430,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. How can I contact Ventyx Biosciences? The official website for the company is www.ventyxbio.com. The company can be reached via phone at 760-593-4832 or via email at ir@ventyxbio.com. This page (NASDAQ:VTYX) was last updated on 6/8/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.